Selinexor Shows Marked Activity in Double-hit Diffuse Large B Cell Lymphoma (DLBCL) in Pre-clinical Models and in Patients with Heavily Pre-treated Relapsed/Refractory Double-hit DLBCL

Selinexor Shows Marked Activity in Double-hit Diffuse Large B Cell Lymphoma (DLBCL) in Pre-clinical Models and in Patients with Heavily Pre-treated Relapsed/Refractory Double-hit DLBCL

Learn More